Bone Cancer - Osteosarcoma / chondrosarcoma / rare subtypes 
Breast Cancer - Subtype defined by an amplification of the HER2 gene 
Breast cancer - Asian phenotype 
Pediatric Brain Tumors - Medulloblasma & Pediatric Pilocytic Astrocytoma 
Brain Cancer - Pediatric Medulloblastoma 
Colorectal cancer - Adenocarcinoma, non-Western 
Oral Cancer - Gingivobuccal 
Thyroid Cancer - Papillary thyroid carcinoma 
Chronic Lymphocytic Leukemia - CLL with mutated and unmutated IgVH 
Liver Cancer - Hepatocellular carcinoma (Virus associated) 
Ovarian Cancer - Serous cystadenocarcinoma 
Rare Pancreatic Tumors - Enteropancreatic endocrine tumors and rare pancreatic exocrine tumors 
| United States: | Broad Institute |
| Mayo Clinic | |
| University of Iowa |
| United States: | Broad Institute |
| Dana Farber Cancer Institute | |
| Mayo Clinic | |
| University of Iowa |
| United States: | National Center for Biotechnology Information |
Sequencing, SNP, copy number, and somatic variant calls will be stored at the NCBI short read archive as well as dbGAP for data sharing and distribution purposes.
Diffuse large B cell lymphoma is an aggressive Non-Hodgkin lymphoma that affects 30,000 new patients in the US every year. The standard of care for the treatment of most cases of DLBCL is chemo-immunotherapy with the “R-CHOP” regimen. Although the 3-year event-free survival is about 60% even for elderly patients between 60-80 years old, the remainder of patients eventually relapse and the majority die of their disease. To date, treatment strategies to improve outcome have largely included increased doses of standard agents in the context of autologous stem cell transplantation. Therefore, there is a great medical need to define the genetic abnormalities that are associated with DLBCL in order to define novel targets for therapy. We are undertaking an effort to characterize 100 DLBCL cases and matched normal controls using whole exome sequencing technology.
Slim Initiative for Genomic Medicine:
This work is conducted as part of the Slim Initiative for Genomic Medicine (SIGMA), a joint U.S.-Mexico project funded by the Carlos Slim Health Institute. The SIGMA cancer project aims to understand the genomic basis of cancer in worldwide populations by extensive analysis of at least 560 cancer pairs across at least 7 different cancers to obtain an initial molecular taxonomy of the mutations present in these cancer types.
Todd Golub
Jens Lohr
James Cerhan